Abevmy 400 Vial — Bevacizumab 400 mg/16 ml (1 Vial) Mylan
Abevmy 400 mg/16 ml (Bevacizumab) is an advanced targeted anti-cancer therapy. It is a monoclonal antibody that selectively binds to the vascular endothelial growth factor (VEGF). By blocking this factor, Abevmy inhibits the development of new blood vessels in the tumor, effectively cutting off its supply of oxygen and nutrients, which stops tumor growth and metastatic spread.
Manufacturer: Mylan (in collaboration with Biocon). 🌍 This drug is a high-quality biosimilar of the original drug Avastin, manufactured under strict international standards for quality and clinical safety. It has undergone rigorous testing to prove therapeutic equivalence to the reference product.
Key Features:
- ✅ Targeted Mechanism: Specifically attacks the tumor's blood supply network while sparing healthy organs.
- ✅ Broad Spectrum: Proven effective for various types of solid tumors.
- ❄️ STRICT TEMPERATURE CONTROL: As a biological product, Abevmy requires continuous "cold chain" management. It must be stored in a refrigerator at 2°C to 8°C. Do not freeze or expose to heat.
Abevmy is prescribed by an oncologist (either alone or with chemotherapy) for the treatment of:
- 🔹 Metastatic colorectal cancer.
- 🔹 Non-small cell lung cancer (NSCLC) — advanced, metastatic, or recurrent.
- 🔹 Metastatic renal cell carcinoma (kidney cancer).
- 🔹 Ovarian, fallopian tube, or primary peritoneal cancer.
- 🔹 Cervical cancer (persistent, recurrent, or metastatic).
- 🔹 Recurrent glioblastoma (brain tumor).
Sales Unit: 1 single-use glass vial containing 400 mg of bevacizumab in 16 ml. Concentrate for solution for intravenous (I.V.) infusion.
⚠️ APPLICATION INSTRUCTIONS:
- Method: For intravenous infusion (drip) only. It must NOT be administered as an intravenous push or bolus.
- Dosage: Strictly individualized based on body weight (typically 5 mg to 15 mg per kg) and the clinical protocol.
- Frequency: Administered usually once every 2 or 3 weeks.
- Storage: Keep in the original carton to protect from light, stored in a refrigerator (2-8°C).
- ⛔ Surgery: Do not start treatment for at least 28 days following major surgery or until the wound is fully healed.
- ⛔ Bleeding: Active severe hemorrhage or recent hemoptysis (coughing up blood).
- Pregnancy and breastfeeding (highly hazardous to the fetus).
- Hypersensitivity to bevacizumab or any excipients.
- Children and adolescents (safety not established).
Treatment requires professional medical supervision. Potential side effects include:
- 🫀 Vascular: High blood pressure (hypertension) — requires regular monitoring.
- 🩸 Hematologic: Nosebleeds, low white blood cell count (neutropenia).
- 🟡 Renal: Protein in the urine (proteinuria).
- ⚠️ General: Impaired wound healing, risk of GI perforation (rare), fatigue.
Similar products
What Customers Say
No reviews yet
Your review can be the first!